Page 2 - Text View News Today

Announced on May 10, 2023, topline results of the phase 2 dose-finding trial for BI 456906 suggests use was associated with reductions in body weight of up to 14.9% during the 46-week study.

/PRNewswire/ -- Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today that based on the most recent...

It is important for pharmacists to understand implications related to drug clearance to maximize therapeutics in patients with kidney disease.

Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio Bringing medicines to patients with rare liver disease, a growth opportunity for IpsenLead asset Bylvay® (odevixibat)

Investegate announcements from Ipsen Pharma, Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

/PRNewswire/ -- Infinant Health, Inc, a company focused on improving infant health through the gut microbiome, today announced the enrollment of the final...

/PRNewswire/ -- Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today the commercial launch and dosing of...

/PRNewswire/ -- Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today the first production batch has been...

- FDA approval of Elucirem™ (NDA 216986) was granted after priority review, a designation assigned to applications for drugs that provide significant...

- FDA approval of Elucirem™ (NDA 216986) was granted after priority review, a designation assigned to applications for drugs that provide significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions compared to available therapies. - In the approved indications, a contrast-enhanced MRI exa...